Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Article in English | MEDLINE | ID: mdl-31700690

ABSTRACT

Introduction: Ganglion impar block (GIB) is a well-recognised treatment for chronic coccydynia. Several side effects have previously been described with this procedure, including transient motor dysfunction, bowel, bladder, and sexual dysfunction, neuritis, rectal perforation, impingement of the sciatic nerve, cauda equina syndrome, and infection. Case presentation: We describe the first report of imaging-documented conus infarction after an unguided-GIB performed in theatre using particulate steroids for a 17-year-old patient with coccydynia. Immediately post-GIB, patient developed transient neurological deficits in her lower limbs of inability to mobilise her legs that lasted for 24 h. These include back and leg pain, decreased power and movement, increased tone, brisk reflexes, reduced light touch sensation and proprioception of legs up to the T10 level. Urgent MRI spine showed intramedullary hyperintense signal within the conus and mild restricted diffusion on the distal cord and conus, suggestive of an acute conus infarction. On follow-up, the GIB did not result in symptom improvement of coccydynia and there was persistent altered sensation of her legs. Discussion: Various approaches of ganglion impar block have been described and performed in the past with different imaging techniques and injectants. A few cases of unusual neurological complications have been reported with the use of epidural steroid injections and ganglion impar block. Clinicians should be aware of the possible neurological complications following ganglion impar blocks and the risk of inadvertent intravascular injection of particulate steroids can potentially to be minimised by using imaging guidance.


Subject(s)
Coccyx/blood supply , Coccyx/diagnostic imaging , Ganglia, Spinal/diagnostic imaging , Glucocorticoids/adverse effects , Infarction/diagnostic imaging , Nerve Block/adverse effects , Adolescent , Chronic Disease , Coccyx/drug effects , Female , Ganglia, Spinal/drug effects , Glucocorticoids/administration & dosage , Humans , Infarction/etiology , Steroids/administration & dosage , Steroids/adverse effects , Triamcinolone Acetonide/administration & dosage , Triamcinolone Acetonide/adverse effects
2.
BMJ Case Rep ; 20152015 Jul 23.
Article in English | MEDLINE | ID: mdl-26206781

ABSTRACT

Atrial myxoma, the commonest primary cardiac neoplasm, presents with symptoms of heart failure, embolic phenomena or constitutional upset. We present an atypical case, with wheeze and symptomatic exacerbations typical of chronic obstructive pulmonary disease. With no early clinical evidence of heart failure, the patient was managed with inhaled steroids and bronchodilators, with little relief. Only when the patient was in extremis requiring intubation, due to respiratory failure, did clinical evidence of left heart failure become apparent, with echocardiography demonstrating a massive left atrial myxoma obstructing the mitral valve annulus. Following successful surgical resection, the patient's symptoms fully abated. This case highlights the importance of considering cardiac wheeze in those initially managed as obstructive airway disease not responding in a typical fashion to initial bronchodilator therapy, and particularly in those with rapidly progressive symptoms. Such patients should be referred early for cardiac imaging. The excellent prognosis and quick recovery after timely surgical resection of a myxoma are also highlighted.


Subject(s)
Heart Atria/diagnostic imaging , Heart Failure/etiology , Heart Neoplasms/complications , Myxoma/complications , Pulmonary Disease, Chronic Obstructive/etiology , Bronchodilator Agents/therapeutic use , Echocardiography , Female , Heart Failure/therapy , Heart Neoplasms/diagnostic imaging , Heart Neoplasms/surgery , Humans , Middle Aged , Myxoma/diagnostic imaging , Myxoma/surgery , Pulmonary Disease, Chronic Obstructive/drug therapy , Steroids/therapeutic use , Treatment Outcome
3.
Stroke ; 45(5): 1422-8, 2014 May.
Article in English | MEDLINE | ID: mdl-24699052

ABSTRACT

BACKGROUND AND PURPOSE: Previous cell-based and animal studies showed mixed tocotrienols are neuroprotective, but the effect is yet to be proven in humans. Thus, the present study aimed to evaluate the protective activity of mixed tocotrienols in humans with white matter lesions (WMLs). WMLs are regarded as manifestations of cerebral small vessel disease, reflecting varying degrees of neurodegeneration and tissue damage with potential as a surrogate end point in clinical trials. METHODS: A total of 121 volunteers aged ≥35 years with cardiovascular risk factors and MRI-confirmed WMLs were randomized to receive 200 mg mixed tocotrienols or placebo twice a day for 2 years. The WML volumes were measured from MRI images taken at baseline, 1 year, and 2 years using a validated software and were compared. Fasting blood samples were collected for full blood chemistry investigation. RESULTS: According to per-protocol (88 volunteers) and intention-to-treat (121 volunteers) analyses, the mean WML volume of the placebo group increased after 2 years, whereas that of the tocotrienol-supplemented group remained essentially unchanged. The mean WML volume change between the 2 groups was not significantly different (P=0.150) at the end of 1 year but was significant at the end of 2 years for both per-protocol and intention-to-treat analyses (P=0.019 and P=0.018). No significant difference was observed in the blood chemistry parameters between the 2 groups. CONCLUSIONS: Mixed tocotrienols were found to attenuate the progression of WMLs. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00753532.


Subject(s)
Leukoencephalopathies/drug therapy , Tocotrienols/pharmacology , Vitamins/pharmacology , Adult , Female , Humans , Leukoencephalopathies/blood , Leukoencephalopathies/pathology , Magnetic Resonance Imaging , Malaysia , Male , Middle Aged , Palm Oil , Plant Oils/administration & dosage , Plant Oils/adverse effects , Plant Oils/pharmacology , Tocotrienols/administration & dosage , Tocotrienols/adverse effects , Treatment Outcome , Vitamins/administration & dosage , Vitamins/adverse effects
6.
Cardiovasc Intervent Radiol ; 33(1): 213-4, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19484289

ABSTRACT

The AMPLATZER Vascular Plug (AVP; AGA Medical, USA) is designed to provide optimal embolization of peripheral veins and arteries through single-device occlusion. There are no reported cases of the AVP's being used to prevent bile leak. We report the successful use of the AVP within the liver to prevent intraperitoneal bile leak following inadvertent subcapsular stent deployment.


Subject(s)
Cholestasis, Intrahepatic/therapy , Embolization, Therapeutic/instrumentation , Foreign Bodies/etiology , Foreign-Body Migration/prevention & control , Palliative Care/methods , Septal Occluder Device , Stents/adverse effects , Aged , Bile Duct Neoplasms/complications , Bile Duct Neoplasms/therapy , Bile Ducts, Intrahepatic , Cholangiocarcinoma/complications , Cholangiocarcinoma/therapy , Cholestasis, Intrahepatic/etiology , Foreign-Body Migration/etiology , Humans , Jaundice, Obstructive/etiology , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...